Welcome to our dedicated page for Cytek Biosciences SEC filings (Ticker: CTKB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cytek Biosciences, Inc. filings document the reporting, governance, and security structure of a Nasdaq-listed cell analysis solutions company. Its registered security is common stock traded under the CTKB symbol on the Nasdaq Global Select Market.
The company’s 8-K filings furnish financial-results releases, preliminary revenue updates, and related exhibit disclosures under Item 2.02. Proxy and annual meeting filings cover director elections, advisory executive compensation votes, auditor ratification, stockholder voting results, board-class matters, and other governance subjects. Together, these filings describe Cytek’s public-company reporting framework alongside its business in FSP instruments, reagents, software, services, and cell analysis technologies.
Boston Partners, a Delaware entity, reports beneficial ownership of Cytek Biosciences, Inc. common stock on a Schedule 13G. It reports holding 7,635,145 shares of common stock, representing 5.91% of the class as of June 30, 2026. Boston Partners has sole voting power and sole dispositive power over all 7,635,145 shares, with no shared voting or dispositive power.
The shares are held in discretionary accounts for certain clients, and Boston Partners may be deemed a beneficial owner under Rule 13d-3. To its knowledge, no other person has rights to dividends or sale proceeds relating to more than 5% of the outstanding common stock referenced.
Cytek Biosciences, Inc. set out separation arrangements for former Chief Legal Officer and Corporate Secretary Valerie Barnett, whose position ended on June 29, 2026. On July 9, 2026, the parties entered into a Severance Agreement including a one-time lump-sum payment of $365,775.12 and payment of COBRA premiums through the earlier of April 30, 2027, or the date she becomes covered under another employer’s group health plan.
If a Change in Control occurs within three months after the Separation Date, Ms. Barnett instead becomes eligible for change-in-control severance equal to 18 months of base salary plus her 2026 bonus target, with the previously paid severance credited, extended COBRA coverage through January 31, 2028, and full vesting of outstanding equity awards. The company also entered into a Consulting Agreement effective July 10, 2026, under which she will provide transition support at $1,000 per hour, up to 10 hours per week, through August 31, 2026, with continued vesting of existing equity awards during her service.
BlackRock, Inc. amended its Schedule 13G to report beneficial ownership of 9,356,551 shares of Cytek Biosciences, Inc. The filing states 9,356,551 shares were beneficially owned, representing 7.2% of the outstanding common stock as of 06/30/2026. The report shows sole voting power of 9,228,737 shares and sole dispositive power of 9,356,551. The filing is signed by a BlackRock managing director on 07/08/2026 and discloses that various persons may have rights to dividends or sale proceeds.
Cytek Biosciences, Inc. filed an initial Form 3 insider ownership report for Ilan Feuchtwang, who serves as Chief Legal Officer and Secretary. The filing is an administrative disclosure of insider status and does not report any share purchases, sales, or other transactions.
Cytek Biosciences, Inc. reports that Valerie Barnett will leave her role as Chief Legal Officer and Corporate Secretary. The company and Ms. Barnett agreed that her position will terminate effective June 29, 2026.
The company states that Ms. Barnett’s separation is not due to any disagreement with its operations, policies, or practices, indicating an orderly leadership transition in its legal and corporate governance functions.
Cytek Biosciences, Inc. director and Chief Technology Officer Yan Ming reported a bona fide gift of common stock. On the reported date, Ming transferred 135,892 shares of Cytek Biosciences common stock as a gift at a stated price of $0.00 per share. After this disposition, Ming continued to hold 4,796,688 shares of common stock directly, indicating that the gifted amount represents a relatively small portion of his overall reported holdings. As a gift transaction, this Form 4 reflects a non-market transfer rather than an open-market purchase or sale.
Cytek Biosciences, Inc. reported the results of its 2026 annual meeting of stockholders held on June 10, 2026. Of 129,142,587 common shares outstanding as of April 13, 2026, 111,161,490 were present or represented by proxy, about 86.1% of shares entitled to vote, establishing a strong quorum.
Three director nominees received more votes for than withheld: Vera Imper, Ph.D. (64,769,976 for; 20,723,477 withheld), Glenn P. Muir (79,599,103 for; 5,894,350 withheld) and Ming Yan, Ph.D. (76,741,063 for; 8,752,390 withheld). Two additional matters were also approved, including one that received 84,794,380 votes for and another that received 110,533,253 votes for, each with relatively few votes against.
Cytek Biosciences director Jack Ball exercised a vested equity award for 43,973 shares of common stock through conversion of Restricted Stock Units. The RSU award fully vested on June 10, 2026, and after this non‑market, compensation-related transaction he directly holds 86,678 shares of Cytek common stock.
Cytek Biosciences director Glenn P. Muir reported equity awards that increase his potential ownership in the company. He received a stock option for 29,835 shares of common stock at an exercise price of $4.05 per share, expiring on June 10, 2036. He also received 55,555 restricted stock units, each representing one share of common stock.
The option vests in equal monthly installments over three years following the June 10, 2026 grant date. The restricted stock units vest in tranches between August 18, 2026 and August 18, 2027 based on a detailed schedule, tying full ownership to continued service.
Cytek Biosciences, Inc. director Glenn P. Muir filed an initial Form 3 beneficial ownership report. The filing identifies him as a director but shows no share purchases, sales, option exercises, gifts, or restructurings, and no derivative positions or holdings are detailed in the provided data.